Medical Device | April 01, 2024
MTD acquires Ypsomed's pen needle and BGM businesses
This acquisition enables MTD to open new, strategic markets
This acquisition enables MTD to open new, strategic markets
The company had earlier announced about the approval received from the MHRA for Liraglutide
The facility will manufacture tablets, capsules, and injections for the oncology segment
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
WINREVAIR is a breakthrough biologic for this rare, progressive disease
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
Vision loss due to Glaucoma can be prevented if it is detected and treated early
The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters
This agreement paves the way for the introduction of YESAFILI into the Canadian market
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Subscribe To Our Newsletter & Stay Updated
